Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group
[December 10, 2020] Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group â¬1.18 billion acquisition provides for significant returns to PPF Group as NBEâs largest shareholder SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE PRAGUE, Czech Republic, Dec. 10, 2020 (GLOBE NEWSWIRE) -- PPF Group, an international investment group, today announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boeh...